Literature DB >> 15118910

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive infections and acute otitis media in children.

Nikolaos P Zissis1, Vassiliki Syriopoulou, Dimitris Kafetzis, George L Daikos, Amalia Tsilimingaki, Emanouel Galanakis, Iraklia Tsangaropoulou.   

Abstract

UNLABELLED: A prospective study was conducted to determine the serotypes and antibiotic resistance patterns of pneumococcal isolates from children with invasive pneumococcal disease (IPD) and acute otitis media (AOM). From October 2001 to May 2002, 65 children with IPD (28 bacteraemic pneumonia, 24 bacteraemia without focus, 7 meningitis, 6 other infections) and 78 with AOM were identified. The most common serotypes causing IPD were 14 (32.3%), 6B (20.0%), 1 (18.5%) and 19F (7.7%) whereas the predominant serotypes causing AOM were 19F (35.9%), 14 (16.7%) and 23F (9.1%). Sixty-nine percent of IPD and 70.5% of AOM were caused by vaccine serotypes. The vaccine serotypes were more commonly encountered in meningitis cases and in children younger than 2 years of age. Intermediate resistance to penicillin was observed in 6 of 65 (9.2%) IPD isolates, one of which was intermediately resistant to cefotaxime (1.6%), whereas none exhibited high-level resistance to penicillin or other beta-lactam antibiotics. A higher proportion of antimicrobial resistance was noted in AOM isolates; 29 of 78 (37.4%) exhibited intermediate resistance and 8 (10.2%) high level resistance to penicillin, four of which had intermediate resistance to cefotaxime. Significant resistance was also noted to erythromycin; 38.5% of IPD and 48.7% of AOM isolates were resistant. Multidrug resistance was observed in one IPD and in eight AOM isolates.
CONCLUSION: these findings have implications in the potential use of 7-valent conjugate vaccine in our region. Copyright 2004 Springer-Verlag

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118910     DOI: 10.1007/s00431-004-1447-4

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

2.  The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

Authors:  W P Hausdorff; J Bryant; C Kloek; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

Review 3.  Resistant pneumococci: protecting patients through judicious use of antibiotics.

Authors:  S F Dowell; B Schwartz
Journal:  Am Fam Physician       Date:  1997-04       Impact factor: 3.292

4.  Pneumococcal acute otitis media in children.

Authors:  G Kouppari; A Zaphiropoulou; G Stamos; V Deliyianni; N Apostolopoulos; N J Legakis
Journal:  Clin Microbiol Infect       Date:  2000-02       Impact factor: 8.067

5.  Epidemiology of invasive childhood pneumococcal infections in Greece.

Authors:  V Syriopoulou; G L Daikos; K Soulis; A Michos; H Alexandrou; I Pavlopoulou; C Hadjichristodoulou; M Theodoridou
Journal:  Acta Paediatr Suppl       Date:  2000-12

6.  Pneumococcal vaccines. WHO position paper.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1999-06-11

7.  Three-year multicenter surveillance of systemic pneumococcal infections in children.

Authors:  S L Kaplan; E O Mason; W J Barson; E R Wald; M Arditi; T Q Tan; G E Schutze; J S Bradley; L B Givner; K S Kim; R Yogev
Journal:  Pediatrics       Date:  1998-09       Impact factor: 7.124

8.  American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis.

Authors:  G D Overturf
Journal:  Pediatrics       Date:  2000-08       Impact factor: 7.124

9.  Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in children with otitis media.

Authors:  M L Joloba; A Windau; S Bajaksouzian; P C Appelbaum; W P Hausdorff; M R Jacobs
Journal:  Clin Infect Dis       Date:  2001-10-04       Impact factor: 9.079

10.  Multinational study of pneumococcal serotypes causing acute otitis media in children.

Authors:  William P Hausdorff; Greg Yothers; Ron Dagan; Terhi Kilpi; Stephen I Pelton; Robert Cohen; Michael R Jacobs; Sheldon L Kaplan; Corinne Levy; Eduardo L Lopez; Edward O Mason; Vassiliki Syriopoulou; Brian Wynne; John Bryant
Journal:  Pediatr Infect Dis J       Date:  2002-11       Impact factor: 2.129

View more
  3 in total

1.  Serotypes and susceptibilities of paediatric clinical isolates of Streptococcus pneumoniae in Crete, Greece, before and after the heptavalent pneumococcal conjugate vaccine.

Authors:  S Maraki; G Samonis; E Galanakis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-07-10       Impact factor: 3.267

2.  Burden of paediatric invasive pneumococcal disease in Europe, 2005.

Authors:  E D G McIntosh; B Fritzell; M A Fletcher
Journal:  Epidemiol Infect       Date:  2006-09-07       Impact factor: 2.451

3.  Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.

Authors:  Daniel R Feikin; Eunice W Kagucia; Jennifer D Loo; Ruth Link-Gelles; Milo A Puhan; Thomas Cherian; Orin S Levine; Cynthia G Whitney; Katherine L O'Brien; Matthew R Moore
Journal:  PLoS Med       Date:  2013-09-24       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.